Half simply stopped taking the medication within a year
At a medical conference in Istanbul, researchers presented findings from nearly 90,000 real-world patients that illuminate a fundamental truth about GLP-1 weight-loss drugs: their protective power is proportional to the weight they help shed, and that power vanishes when the medications are abandoned. The study, led by Professor John Wilding at the University of Liverpool, traces a quiet human drama unfolding across the American health system — one in which half of all patients stop treatment within a year, surrendering gains that might have shielded them from some of the body's most burdensome chronic conditions. It is a story not just about pharmacology, but about the gap between what medicine can offer and what daily life allows people to sustain.
- Half of the nearly 90,000 patients studied stopped taking their GLP-1 medication within a year — a discontinuation rate that undermines the very protection these drugs are designed to provide.
- Patients who gained weight on these treatments faced a 69% higher risk of heart failure compared to those who achieved even modest weight loss, making non-adherence a medically consequential decision.
- Those who lost 15% or more of their BMI saw dramatic risk reductions — 37% less osteoarthritis, 69% less sleep apnea — revealing a clear dose-response relationship between weight lost and harm avoided.
- The study's real-world design captured actual patient behavior rather than clinical-trial ideals, exposing how side effects, cost, and the friction of daily life erode the theoretical promise of these medications.
- Researchers are now pressing the case that sustained adherence and meaningful weight loss are inseparable from the drugs' benefits, urging health systems to better support patients in staying the course.
At a medical conference in Istanbul this May, Professor John Wilding and his team at the University of Liverpool presented findings drawn from nearly 90,000 American patients who began GLP-1 treatment between early 2021 and mid-2024. Their question was not whether these drugs work in controlled conditions — that is already established — but what actually happens when real people, with real lives, take them.
The patients studied had an average age of 57 and a starting BMI of 34.7; sixty-one percent had type 2 diabetes. Over roughly two years, the researchers tracked weight changes in the first year and then monitored for four serious conditions: osteoarthritis, chronic kidney disease, obstructive sleep apnea, and heart failure. The pattern that emerged was consistent and striking. Patients who lost at least 15% of their BMI saw a 37% lower risk of osteoarthritis and a 69% lower risk of sleep apnea compared to those who lost less than 5%. Kidney disease risk fell by 30%, and heart failure by 32%, though the latter narrowly missed statistical significance.
The reverse was equally sobering. Patients who gained weight faced a 69% higher risk of heart failure and meaningful increases in sleep apnea and kidney disease risk. The incidence rates across the follow-up period — roughly 21 cases of osteoarthritis and kidney disease per 1,000 person-years, and nearly 4 cases of heart failure — gave weight to what the percentages implied.
What distinguished this study was its unflinching look at real behavior. Half of all patients stopped taking their medication within a year, defined as a gap of 60 days or more without a refill. The researchers included them all. The conclusion was direct: the drugs offer genuine, graded protection — but only for those who keep taking them and for whom the weight actually moves. The gap between clinical promise and lived reality remains the central challenge these findings leave unresolved.
At a medical conference in Istanbul this May, researchers presented findings that should matter to anyone taking—or considering—a GLP-1 drug for weight loss or diabetes. The story is straightforward but consequential: the more weight you lose on these medications, the lower your risk of developing serious complications. But there's a catch. Half the people who start these drugs stop taking them within a year, and when that happens, the protection disappears.
Professor John Wilding and his team at the University of Liverpool analyzed nearly 90,000 patients in the United States who began GLP-1 treatment between early 2021 and mid-2024. These drugs—semaglutide, liraglutide, and tirzepatide—have become central to obesity and diabetes care. In controlled trials, they work. But the researchers wanted to know what actually happens in the real world, where people's lives are messier than clinical protocols. They tracked patients for roughly two years, measuring how much weight they lost in the first year and then watching for four serious conditions: osteoarthritis, chronic kidney disease, obstructive sleep apnea, and heart failure.
The numbers tell a dose-response story. Among the 89,718 patients studied, the average age was 57 and the average starting BMI was 34.7—solidly obese. Sixty-one percent had type 2 diabetes. In that first year, some patients lost substantial weight. Others lost a little. Some gained weight. And half simply stopped taking the medication, defined as a gap of 60 days or longer without a refill. The researchers didn't exclude those people; they analyzed everyone based on what actually happened to their weight.
The pattern that emerged was clean. Patients who lost at least 15 percent of their BMI saw their risk of osteoarthritis drop by 37 percent compared to those who lost less than 5 percent. For sleep apnea, the reduction was even starker: 69 percent lower risk. Chronic kidney disease risk fell by 30 percent. Even heart failure, the rarest of the four conditions, showed a 32 percent reduction, though this result didn't quite reach statistical significance. The message was consistent across all four conditions: more weight loss meant more protection.
The flip side was equally important. Patients who gained weight faced worse odds. Those whose BMI increased had a 69 percent higher risk of heart failure compared to minimal weight losers. Their risk of sleep apnea rose by 22 percent. Chronic kidney disease risk climbed 14 percent. Osteoarthritis risk edged up 10 percent, though this last finding wasn't statistically significant. The incidence rates themselves were sobering: over an 11-month follow-up period after that first year, there were 21.4 cases of osteoarthritis per 1,000 person-years, 21.1 cases of kidney disease, 20.3 cases of sleep apnea, and 3.9 cases of heart failure.
What makes this study distinct is that it captures real behavior, not ideal behavior. These weren't patients in a controlled trial taking pills under supervision. They were people in the actual health system, making actual decisions about whether to keep taking expensive medications with side effects. Half of them decided to stop. The researchers' conclusion was direct: in the real world, where half of patients discontinue treatment within a year, failing to lose weight was associated with worse outcomes, while larger weight reductions were associated with better ones. The implication hung in the air: the drugs work, but only if you keep taking them and if they actually move the needle on your weight.
Citações Notáveis
In this real-world study where half of patients discontinued GLP-1-based treatment within a year after initiation, not losing weight was associated with worse clinical outcomes while larger reductions were associated with decreased risks.— Professor John Wilding, University of Liverpool
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that half the patients stopped taking these drugs? Couldn't the study just look at the people who stuck with it?
Because that would tell you nothing about what actually happens to people. In a trial, you can mandate adherence. In real life, people stop because of side effects, cost, or just losing motivation. If you only studied the half who stayed on the drugs, you'd miss the half of the population that matters most—the ones who quit.
So the study is really about adherence, not about the drugs themselves?
It's about both. The drugs work—the data shows that clearly. But they only work if you take them. The study is saying: here's what the drugs can do, and here's what actually happens when people use them the way they really do.
The heart failure numbers are striking. Sixty-nine percent higher risk if you gain weight. That's a big jump.
It is. Heart failure is rare in this population—only 3.9 cases per thousand person-years—but when weight goes up instead of down, the risk nearly doubles. That's the body telling you something about what obesity does to the heart.
What about the people who lost a little weight but not a lot? They seem to be the baseline for comparison.
Right. The study treats minimal weight loss—less than 5 percent of BMI—as the reference point. Everyone else is compared to them. So you're not looking at people who failed; you're looking at a gradient. A little loss is better than no loss. More loss is better still. It's proportional.
Does this change how doctors should think about these drugs?
It suggests that the goal shouldn't just be to start the drug. It should be to help patients stay on it and achieve meaningful weight loss. The drugs are tools, but they require follow-through. That's the real-world lesson.